So what do you see, kind of, how are these leveraged by the different companies? Is this, this embraced, or is it still some kind of outlier here and there or what's the status of R-based submissions?

Right.

Yeah.

Maybe I can first give a overview about the pilot that we are running, and then I can also share that, like, how the good practice evolve over time, like based on our learnings, et cetera.

So for R Consortium Submission Working Group, right now we are at pilot six and seven.

We already finished four pilots.

There are four pilots that already have FDA response letter.

But what's your perception up to now?